 |
|
A Pilot Study of Buspirone in Attention-Deficit Hyperactivity Disorder
Louis H. McCormick, MD;
Gaspard T. Rizzuto, PhD;
Hope B. Knuckles
Arch Fam Med. 1994;3(1):68-70.
Abstract
Our safety and efficacy of buspirone hydrochloride in the treatment of attention-deficit hyperactivity disorder. We designed a 4-week, doubleblind, placebo-controlled study. In a rural community, 10 students with attentiondeficit hyperactivity disorder diagnosed by Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria were seen in a private, office-based practice. Patients were randomly assigned to a 2-week treatment with either placebo or buspirone, followed by a 2-week treatment with the other condition and with each subject acting as his own control. Results were measured by Conners' Abbreviated Teacher Rating Scales with statistical analysis by twoperiod, repeated measurements crossover design. Buspirone therapy was found to be safe and effective. Nine of the 10 students improved while receiving buspirone with only minimal side effects. This pilot study shows a beneficial effect of buspirone in the treatment of attention-deficit hyperactivity disorder and calls for additional research to further define the role of buspirone in clinical practice.
Author Affiliations
From Acadiana Family Practice Associates, Franklin, La (Dr McCormick), and the Department of Statistics, University of Southwestern Louisiana, Lafayette (Dr Rizzuto and Ms Knuckles).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment With Buspirone in a Patient With Autism
McCormick
Arch Fam Med 1997;6:368-370.
ABSTRACT
|
